We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
US start-up Phlow has been approved to join the Biomedical Advanced Research and Development Authority's (BARDA) CDMO network to provide domestic API manufacturing capability for essential medicines and medical countermeasures.
US-based public benefit drug manufacturing corporation Phlow has received $354m funding from the government to produce essential medicines at risk of shortage amid the Covid-19 pandemic.